Pacira BioSciences (PCRX) EBT (2010 - 2026)

Pacira BioSciences has reported EBT for 17 years, with the latest figure at $2.6 million in Q2 2026.

• On a quarterly basis, EBT rose 232.59% year-over-year to $2.6 million in Q2 2026; TTM through Jun 2026 was $17.6 million, a 116.56% increase from a year earlier, with the FY2025 full-year figure at $16.9 million, up 126.74% from the prior year.
• EBT was $2.6 million for Q2 2026 at Pacira BioSciences, down from $5.0 million in the prior quarter.
• The five-year high for EBT was $37.9 million in Q2 2023, with the low at -$138.9 million in Q3 2024.
• Average EBT over 5 years is $2.0 million, with a median of $8.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: EBT soared 702.37% in 2023, then plunged 936.43% in 2024.
• Over 5 years, EBT stood at -$18.1 million in 2022, then jumped by 286.63% to $33.7 million in 2023, then fell by 24.3% to $25.5 million in 2024, then plunged by 97.76% to $571000.0 in 2025, then soared by 347.46% to $2.6 million in 2026.
• The last three EBT figures came in at $2.6 million (Q2 2026), $5.0 million (Q1 2026), and $571000.0 (Q4 2025), per Business Quant data.